ESR1 and breast carcinoma: A previous study evaluated LKB1 expression in metastatic estrogen receptor (ER)-positive breast cancer samples (n = 55) from the TAMRAD trial6,and observed that low LKB1 expression was predictive of everolimus efficacy.